T. Rowe Price Investment Management
MPLT

T. Rowe Price Investment Management’s MapLight Therapeutics MPLT Stock Holding History

T. Rowe Price Investment Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.7M Sell
2,781,728
-20,209
-0.7% -$581K 0.07% 273
2026
Q1 		$57M Buy
2,801,937
+2,757
+0.1% +$49.3K 0.04% 330
2025
Q4 		$49.2M Buy
+2,799,180
New +$46.9M 0.03% 365

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

T. Rowe Price Investment Management's MPLT Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its MapLight Therapeutics (MPLT) stake by 0.72% in Q2 2026, selling an estimated $581K and leaving 2,781,728 shares worth $99.7M. The position accounts for 0.07% of the portfolio, ranked #273.

T. Rowe Price Investment Management first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • T. Rowe Price Investment Management held 2,781,728 shares of MapLight Therapeutics worth $99.7M as of Q2 2026.
  • T. Rowe Price Investment Management sold 20,209 MapLight Therapeutics shares in Q2 2026, an estimated $581K.
  • MapLight Therapeutics made up 0.07% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #273 holding.
  • T. Rowe Price Investment Management first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.